Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL
Open Access
- 3 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medical Genomics
- Vol. 13 (1), 1-7
- https://doi.org/10.1186/s12920-020-0709-y
Abstract
Background The use of high-throughput analytical techniques has enabled the description of acute lymphoblastic leukaemia (ALL) subtypes. The TCF3-HLF translocation is a very rare rearrangement in ALL that is associated with an extremely poor prognosis. The TCF3-HLF fusion gene in the described case resulted in the fusion of the homeobox-related gene of TCF3 to the leucine zipper domain of HLF. The TCF3-HLF fusion gene product acts as a transcriptional factor leading to the dedifferentiation of mature B lymphocytes into an immature state (lymphoid stem cells). This process initiates the formation of pre-leukaemic cells. Due to the rarity of this chromosomal aberration, only a few cases have been described in the literature. The advantage of this work is the presentation of an interesting case of clonal evolution of cancer cells and the cumulative implications (diagnostic and prognostic) of the patient's genetic alterations. Case presentation This work presents a patient with diagnosed with TCF3-HLF-positive ALL. Moreover, the additional genetic alterations, which play a key role in the pathogenesis of ALL, were detected in this patient: deletion of a fragment from the long arm of chromosome 13 (13q12.2-q21.1) containing the RB1 gene, intragenic deletions within the PAX5 gene and NOTCH1 intragenic duplication. Conclusions A patient with coexistence of chromosomal alterations and the TCF3-HLF fusion has not yet been described. Identifying all these chromosomal aberrations at the time of diagnosis could be sufficient to determine the cumulative effects of the described deletions on the activity of other oncogenes or tumour suppressors, as well as on the clinical course of the disease. On the other hand, complex changes in the patient's karyotype and clonal evolution of cancer cells call into question the effectiveness of experimental therapy.Funding Information
- STRATEGMED (STRATEGMED3/304586/5/NCBR/2017)
This publication has 23 references indexed in Scilit:
- Resistance of t(17;19)‐acute lymphoblastic leukemia cell lines to multiagents in induction therapyCancer Medicine, 2019
- NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemiaEpigenomics, 2018
- The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemiaNature Genetics, 2017
- Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical featuresHaematologica, 2013
- A novel TCF3-HLF fusion transcript in acute lymphoblastic leukemia with a t(17;19)(q22;p13)Cancer Genetics, 2012
- The molecular basis of T cell acute lymphoblastic leukemiaJCI Insight, 2012
- The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemiaBlood Reviews, 2012
- PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemiaBlood Cells, Molecules, and Diseases, 2011
- Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19Leukemia, 2006
- Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2000